Associated Papers
Clinical and Genetic Landscape of Glioblastoma, IDH-Wildtype With FGFR Gene Family Alterations.
Kegoya Y et al.
Cancer Science, 2026
The FGFR1 N546K mutation confers resistance to pemigatinib in MLN-ZMYM2::FGFR1.
Shoumariyeh K et al.
Leukemia, 2026
Proteome-Wide Analysis of Functional Phosphosites in the FGFR Family of Proteins: Insights from Large-Scale Phosphoproteomic Analysis.
Palollathil A et al.
Proteomes, 2026
Integrating evidence from protein domains to identify cancer driver mutations.
Ostroverkhova D et al.
Protein Science : a Publication of the Protein Society, 2026
FGFR Testing in Metastatic Urothelial Carcinoma-Who, When, and How to Test.
Mansinho A et al.
Cancers, 2026
PTPN11-Related Noonan Syndrome Predisposes to Multifocal Low-Grade CNS Tumors Harboring FGFR1 Variants.
Kohanbash G et al.
Research Square, 2026
Diffuse low-grade glioma with a rare BRAF p.T599dup mutation in a child: importance of clinicopathological and molecular correlation.
Yamada S et al.
Brain Tumor Pathology, 2026
Saturation mutagenesis identifies activating and resistance-inducing FGFR kinase domain mutations.
Tangermann C et al.
Nature Genetics, 2026
Investigation of a global mouse methylome atlas reveals subtype-specific copy number alterations in pediatric cancer models.
Schoof M et al.
Nature Genetics, 2026
A prospective, multicenter, comprehensive genomic profile signature study in patients with EGFR-mutant advanced non-small cell lung cancer at the first-line treatment failure of osimertinib.
Shi Y et al.
Signal Transduction and Targeted Therapy, 2025
FGFR1 Mutations Are Rare Alternate Oncogenic Drivers in FOXL2 -Wildtype Adult Granulosa Cell Tumors of the Ovary.
Kolin DL et al.
The American Journal of Surgical Pathology, 2025
Concurrence of FGFR1 mutations modulates oncogenesis in glioneuronal tumors.
Boni J et al.
The Embo Journal, 2025
Pemigatinib for previously treated metastatic or unresectable central nervous system tumors with fibroblast growth factor receptor mutations or rearrangements: FIGHT-207 results.
Spanggaard I et al.
The Oncologist, 2025
Clinical outcomes and genomic alterations in patients with metastatic malignant phyllodes tumors.
Takigawa A et al.
Japanese Journal of Clinical Oncology, 2025
Histopathologic Features and Molecular Markers of Encephalocraniocutaneous Lipomatosis (ECCL).
Venigalla S et al.
Dermatopathology (basel, Switzerland), 2025
Discriminating activating, deactivating and resistance variants in protein kinases.
Singh G et al.
Genome Medicine, 2025
Diffuse leptomeningeal glioneuronal tumour: molecular diagnosis, evolution and treatment.
Campanelli A et al.
Acta Neuropathologica Communications, 2025
Molecular Landscape of Pediatric Low-Grade Gliomas: Insights From RNA-NGS and Bioinformatic Analysis.
Brož P et al.
Genes, Chromosomes & Cancer, 2025
Encephalocraniocutaneous lipomatosis-a neuroradiological perspective.
Patel DD et al.
Pediatric Radiology, 2025
A diverse landscape of FGFR alterations and co-mutations suggests potential therapeutic strategies in pediatric low-grade gliomas.
Apfelbaum AA et al.
Nature Communications, 2025
Prevalence and biological impact of clinically relevant gene fusions in head and neck cancers.
Hoskins EL et al.
Npj Precision Oncology, 2025
Selective degradation of FGFR1/2 overcomes antiestrogen resistance in ER+ breast cancer with FGFR1/2 alterations.
Uemoto Y et al.
Cancer Letters, 2025
Case Series of Patients With FGFR1-Related Pheochromocytoma and Paraganglioma With a Focus on Biochemical, Imaging Signatures and Treatment Options.
Jhawar S et al.
Clinical Endocrinology, 2025